Vassiliki Papadimitrakopoulou
SWOG Cancer Research Network
9
9
7
N/A
0
3
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+7 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Marc Dall'Era
University of California, Davis
Shared therapeutic areas:
Worked with same sponsors:
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Kenneth Offit, MD, MPH
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Tanguy Seiwert
University of Chicago Comprehensive Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Sarina A Piha-Paul
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Karen H. Lu, MD, PhD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Heather H. Cheng
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Joanne A. de Hullu, MD, PhD
Radboud University Medical Center
Shared therapeutic areas:
Rosella P.M.G. Hermens, MD,PhD
Radboud University Medical Center
Shared therapeutic areas:
Elizabeth M. Swisher, MD, PhD
University of Washington
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
All 9 trials loaded